Klaviyo increased the suggested price of its shares ahead of its initial public offering (IPO) this week as it brings a fully diluted valuation of roughly $9bn into its sights. This debut follows hot on the heels of the much-talked-about Arm IPO, which occurred on 14 September.
Klaviyo bumps up share pricing ahead of market debut
The company plans to list approximately 19.2 million shares for between $27 and $29 each, a $2 raise from its earlier indication of between $25 and $27. Nearly 20 times oversubscribed on the back of investor interest, experts are predicting a strong start on the New York Stock Exchange (NYSE).
The positive response to the Arm IPO on the Nasdaq raised hopes that this heralds a revival in the typical IPO slump of the past few years. However, the less-than-enthusiastic reception of the Neumora Therapeutics debut put a slight damper on the excitement.
Don’t miss out the latest news, subscribe to LeapRate’s newsletter
Klaviyo decided to raise its pricing after Instacart, another IPO competitor, bumped up its price range on Friday. Notably, Softbank, the Arm parent company, did not increase its IPO pricing prior to the launch as it followed advisor suggestions to forgo the $1 per share increase, despite it equalling roughly $1bn.
September has been kind to US-based IPOs so far, and on average, they made more than $5bn, according to Dealogic statistics. Analysts are holding their breath for another impactful launch. BlackRock manages the Klaviyo assets, and AllianceBernstein hinted at buying up to $100m in shares.
